Stableford Capital II LLC Makes New Investment in Biogen Inc. $BIIB

Stableford Capital II LLC acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 6,914 shares of the biotechnology company’s stock, valued at approximately $1,217,000.

A number of other large investors also recently made changes to their positions in BIIB. Convergence Investment Partners LLC acquired a new stake in shares of Biogen during the third quarter worth $1,342,000. Caprock Group LLC acquired a new position in shares of Biogen in the third quarter valued at about $742,000. Pitcairn Co. bought a new position in Biogen during the second quarter worth about $936,000. Fluent Financial LLC acquired a new stake in Biogen in the 3rd quarter worth about $3,578,000. Finally, Leuthold Group LLC acquired a new stake in Biogen in the 3rd quarter worth about $3,294,000. Institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

BIIB has been the topic of a number of analyst reports. Citigroup increased their target price on shares of Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Wells Fargo & Company boosted their price target on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a research note on Sunday, February 8th. Piper Sandler increased their price target on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. BMO Capital Markets lifted their price objective on Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a report on Friday, February 6th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biogen presently has an average rating of “Hold” and an average target price of $205.31.

Biogen Stock Up 1.0%

NASDAQ BIIB opened at $191.06 on Friday. The business has a fifty day moving average price of $184.98 and a two-hundred day moving average price of $169.76. The stock has a market capitalization of $28.04 billion, a PE ratio of 21.69, a PEG ratio of 1.50 and a beta of 0.15. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the company posted $3.44 EPS. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.